the PsiGAD1 clinical trial, designed to assess Incannex’s psilocybin-assisted psychotherapy for the treatment of generalised anxiety disorder (“GAD”), has achieved its interim milestone of 29 patients completing primary endpoint assessments. Independent analysis of the interim study data has commenced.
Source: Pharmaceutical Industry News | BioSpace